

whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:

Hayden IR

Brett Maas

646-536-7331

Email: brett@haydenir.com

Media Contact:

Ryan@stoxmedia.com

954-699-7611



News Provided by GlobeNewswire via QuoteMedia

Eric Weisblum, CEO of Silo Pharma stated "We are excited to partner with Dr. Denny and Columbia University, a world-renowned institution that is at the forefront of research and development in this area. To be able to bring hope and possibly a therapeutic to patients suffering from Alzheimer's disease is an exciting proposition for Silo Pharma. The unique compounds being developed at Columbia have shown tremendous promise, and we look forward to continuing to explore and develop this therapeutics."

Watch the Breaking News from **Mcap MediaWire** and PsychedelicStox :

<https://youtu.be/1PI61I7LLM>

Click here to read more about all the exciting developments at SILO

Safe Harbor and Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential" and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. ("Silo" or "the Company") to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation,

whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:

Hayden IR

Brett Maas

646-536-7331

Email: brett@haydenir.com

Media Contact:

Ryan@stoxmedia.com

954-699-7611



News Provided by GlobeNewswire via QuoteMedia

Eric Weisblum, CEO of Silo Pharma stated "We are excited to partner with Dr. Denny and Columbia University, a world-renowned institution that is at the forefront of research and development in this area. To be able to bring hope and possibly a therapeutic to patients suffering from Alzheimer's disease is an exciting proposition for Silo Pharma. The unique compounds being developed at Columbia have shown tremendous promise, and we look forward to continuing to explore and develop this therapeutics."

Watch the Breaking News from **Mcap MediaWire** and PsychedelicStox :

<https://youtu.be/1PI61I7LLM>

Click here to read more about all the exciting developments at SILO

Safe Harbor and Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential" and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. ("Silo" or "the Company") to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation,

whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:

Hayden IR

Brett Maas

646-536-7331

Email: brett@haydenir.com

Media Contact:

Ryan@stoxmedia.com

954-699-7611



News Provided by GlobeNewswire via QuoteMedia